Conclusions
Preventable ADRs are a common and important cause of hospitalisation and in-patient’s morbidity and mortality in Nigeria. NSAIDs and OHA were the most commonly implicated drugs resulting in upper GI bleeding and hypoglycaemia respectively. The most common life-threatening ADRs that resulted in the highest number of deaths were caused by antimicrobial agents and herbal medications. Enlightenments campaign against irrational drugs use among the people, and strategic planning for intense follow up of ADRs in Nigeria are advocated.
Acknowledgment
The abstract from the study was presented at International Society for Pharmacoepidemiology (ISPE) Conference of Pharmacoepidemiology and Therapeutic Rick (ICPE) in Philadelphia, USA, in August 2019.
Author Contributions
ADAA conceived the research, was actively involved with data collection, analysis, interpretation, and drafting of the research paper. WAA participated in the development of the research, data collection, data analysis, interpretation and preparation of the first draft of the research paper. IAA and KSA participated in development of the manuscript. All authors read and approved the final manuscript.
Ethical approval
Approval for this study was given by the University of Ibadan/University College Hospital (UI/UCH) Institution Review Board (IRB) and Ethics Review committee. Written informed consent was obtained from study participants.
Conflict of Interest
The authors declare no conflict of interest
Funding
The authors received no funding for this work.
Data availability
The data is available with the corresponding author on request
REFERENCES
1. Camargo AL, Ferreira MBC, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol. 2006;62(2):143-9.
2. Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. Drug Saf. 2016;39(9):847-57.
3. Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681-95.
4. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-58.
5. Davies E, Green C, Mottram D, Pirmohamed M. Adverse drug reactions in hospital in‐patients: a pilot study. J Clin Pharm Ther. 2006;31(4):335-41.
6. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother.2008;42(7):1017-25.
7. Khan LM, Al-Harthi SE, Saadah OI, Al-Amoudi AB, Sulaiman MI, Ibrahim IM. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital. Saudi Med J. 2012;33(8):863-8.
8. Mehta U, Durhein D, Blockman M, Kredo T, Grunden R, Barnes K. Adverse drug reactions in adult medical in patients in a South African hospital serving a community with a high HIV/AIDs prevalence: prospective observational study. Br J Clin Pharmacol 2008;65:396-406. Br J Clin Pharmacol 2008;65:11.
9. Salami T, Asalu A, Samuel S. Prevalence of cutaneous drug eruptions in adult Nigerians with HIV/AIDS. Niger Postgrad Med J. 2010;17(2):160.
10. Adedapo A, Ademowo O, Adedapo K, Demissie K, Osinubi O. Potential toxicity of Chlorpheniramine plus chloroquine for the treatment of childhood malaria. Niger J Clin Pract. 2009;12(3).
11. Ashaye A, Adedapo A, Olusanya B, Adeoti C. Conjunctival hyperaemia and other ocular adverse effects on healthy African subjects after single dosing with 0.004% Travoprost. Afr J Med Med Sci. 2007;36(1):37-42.
12. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9:14.
13. Bello SO, Umar MT. Knowledge and attitudes of physicians relating to reporting of adverse drug reactions in Sokoto, north-western Nigeria. Ann Afr Med. 2011;10(1):13-8.
14. Okezie EO, Olufunmilayo F. Adverse drug reactions reporting by physicians in Ibadan, Nigeria. Pharmacoepidemiol Drug Saf. 2008;17(5):517-22.
15. Ohaju-Obodo JO, Iribhogbe OI. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. Pharmacoepidemiol Drug Saf. 2010;19(2):191-5.
16. Organization WH. Safety of Medicines: A guide to detecting and reporting adverse drug reactions. Geneva: World Health Organization; 2002 2002. WHO/EDM/QSM/2002.2.
17. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228(2):83-90.
18. Organization WH. The Uppsala Monitoring Centre. Safety monitoring of medicinal products. Guidelines for setting up and running a Pharmacovigilance Centre. 2000.
19. Rawlins M, Thompson J. Pathogenesis of adverse drug reactions. Textbook of Adverse Drug Reactions. 1977:10-31.
20. Maxwell S. Therapeutics and good prescribing, Adverse outcomes of drug therapy. In: Davidson’s Principles and Practice of Medicine. 22nd Edition. Editors Walker BR, Colledge NR, Ralston SH, Penman ID. Churchill Livingstone Elsevier Edinburgh 2014 pg18-39.
21. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ.2004;329(7456):15-9.
22. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437-53.
23. Alvarez PA, Bril F, Castro V, Meiville I, Gonzalez CD, Centurion IG, et al. Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina. Int J Risk Saf Med. 2013;25(3):185-92.
24. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol. 2018;9:350.
25. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Bégaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000;56(2):181-6.
26. Camargo AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol. 2006;62(2):143-9.
27. Tumwikirize WA, Ogwal-Okeng JW, Vernby A, Anokbonggo WW, Gustafsson LL, Lundborg SC. Adverse drug reactions in patients admitted on internal medicine wards in a district and regional hospital in Uganda. Afr Health Sci. 2011;11(1):72-8.
28. Awofisayo O, Awofisayo O, Iferi I, Akpan O. The pattern of sale and use of non-steroidal anti-inflammatory drugs in rural and urban centres in Nigeria. Trop J Pharmaceut Res. 2008;7(3):1013-8.
29. Rukewe A, Otegbayo JA, Fatiregun A. Clinical characteristics and outcome of patients with upper gastrointestinal bleeding at the emergency department of a tertiary hospital in Nigeria. Ann Ib Postgrad Med. 2015;13(2):89-93.
30. Mouton JP, Njuguna C, Kramer N, Stewart A, Mehta U, Blockman M, et al. Adverse drug reactions causing admission to medical wards: A cross-sectional survey at 4 hospitals in South Africa. Medicine (Baltimore). 2016;95(19).
31. Awodele O, Aliu R, Ali I, Oni Y, Adeyeye CM. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria. Pharmacol Res Perspect. 2018;6(5):e00427-e00427.
32. Saka B, Gnassingbe W, Akakpo S, Mahamadou G, Teclessou J, Mouhari-Toure A, et al. Reasons for inpatient admissions to the dermatology department in Lomé, Togo : Trends between 1992 to 2005 and 2005 to 2016. Med Sante Trop. 2018;28(3):270-2.
33. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147-6.
34. Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, Gonazalez O, Gonazalez-Herrada C, et al. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol. 2019;75(2):237-46.
35. Saka B, Barro-Traoré F, Atadokpédé FA, Kobangue L, Niamba PA, Adegbidi H, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575-9.
36. Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25(8):402-11.
37. Carr DF, Bourgeois S, Chaponda M, Takeshita LY, Morris AP, Castro EM, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother. 2017;72(4):1152-62.
38. Kiguba R, Ononge S, Karamagi C, Bird SM. Herbal medicine use and linked suspected adverse drug reactions in a prospective cohort of Ugandan inpatients. BMC Complement Altern Med. 2016;16:145.
39. Kiguba R, Karamagi C, Bird SM. Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients. BMJ Open. 2017;7(1):e010568-e010568.
40. van Hunsel F, van de Koppel S, Skalli S, Kuemmerle A, Teng L, Wang JB, et al. Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase. Front Pharmacol. 2019;10:1326.
41. Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83-94.
42. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Saf. 2008;31(9):789-98.
43. Sneha SG, Simhadri K, Subeesh VK, Sneha SV. Predictors of adverse drug reactions in geriatric patients: An exploratory study among cancer patients. South Asian J Cancer. 2019;8(2):130-3.
44. Chan SL, Ang X, Sani LL, Ng HY, Winther MD, Liu JJ, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharmacol. 2016;82(6):1636-46.
Table 1: Sociodemographic characteristics of the patients admitted into the medical wards